- Peginterferon-alpha and Ribavirin Combination Therapy in Chronic Hepatitis C
-
Han KH, Yoon YH
- KMID: 760535
- Korean J Hepatol.
- 2004 Jun;10(2):81-87.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment of Chronic Hepatitis C
-
Chang YJ, Byun KS
- KMID: 772701
- Korean J Gastroenterol.
- 2004 Dec;44(6):301-307.
Chronic infection with HCV represents second most common cause of end-stage liver diseases and hepatocellular carcinoma in Korea. The introduction of new agents and regimens for the treatment of chronic... -
- CITED
-
- Close
- SHARE
-
- Close
- Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients
-
Chung WJ
- KMID: 1392905
- Clin Mol Hepatol.
- 2012 Sep;18(3):268-271.
- doi: 10.3350/cmh.2012.18.3.268
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment of Chronic Hepatitis C: Shorter Treatment Duration for Genotype 2 or 3 Infection
-
Jeong SH
- KMID: 760731
- Korean J Hepatol.
- 2007 Sep;13(3):301-303.
- doi: 10.3350/kjhep.2007.13.3.301
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- New Therapeutic Agent for Chronic Hepatitis C: Direct Acting Agent
-
Chae HB
- KMID: 2373305
- Korean J Gastroenterol.
- 2015 Jul;66(1):5-9.
- doi: 10.4166/kjg.2015.66.1.5
Peg-interferon and ribavirin has been the standard therapy of chronic hepatitis C for the past 15 years in Korea. However, the treatment paradigm is changing. Direct acting agents (DAAs) are... -
- CITED
-
- Close
- SHARE
-
- Close
- Durability of antiviral therapy for chronic hepatitis C after achieving sustained virological response
-
Heo J
- KMID: 1025196
- Korean J Hepatol.
- 2011 Sep;17(3):180-182.
- doi: 10.3350/kjhep.2011.17.3.180
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatitis C Virus and Antiviral Drug Resistance
-
Kim S, Han KH, Ahn SH
- KMID: 2412093
- Gut Liver.
- 2016 Nov;10(6):890-895.
- doi: 10.5009/gnl15573
Since its discovery in 1989, hepatitis C virus (HCV) has been intensively investigated to understand its biology and develop effective antiviral therapies. The efforts of the previous 25 years have... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Vasculitis in Chronic Hepatitis C Patient Treated with Pegylated Interferon Alpha-2a and Ribavirin
-
Kim YH, Han WS, Lee SJ, Oh SN, Choi DW, Byun KS, Yeon JE
- KMID: 760744
- Korean J Hepatol.
- 2007 Sep;13(3):419-422.
- doi: 10.3350/kjhep.2007.13.3.419
There has been an increase in the number of patients treated with pegylated interferon (PEG-IFN) and ribavirin due to the better antiviral efficacy. The main serious adverse events of PEG-IFN... -
- CITED
-
- Close
- SHARE
-
- Close
- Pegylated Interferon-Associated Severe Retinopathy in a Patient with Chronic Hepatitis
-
Kang HY, Shin MC
- KMID: 1364871
- Korean J Ophthalmol.
- 2012 Apr;26(2):147-150.
- doi: 10.3341/kjo.2012.26.2.147
This paper reports a case of pegylated interferon-associated retinopathy in a patient with chronic hepatitis C. A 32-year-old female with chronic hepatitis C undergoing pegylated interferon and ribavirin combination therapy... -
- CITED
-
- Close
- SHARE
-
- Close
- Chronic Hepatitis C and Insulin Resistance
-
Chung WJ
- KMID: 1364829
- Korean J Gastroenterol.
- 2012 Apr;59(4):268-274.
- doi: 10.4166/kjg.2012.59.4.268
Insulin resistance is frequently associated with chronic liver disease, and the interaction between hepatitis C virus (HCV) infection and insulin resistance is a major public health issue, bound to increase... -
- CITED
-
- Close
- SHARE
-
- Close
- The effect of alanine aminotransferase dynamics on predicting sustained virological response in chronic hepatitis C virus infection
-
Kim TY
- KMID: 1372648
- Korean J Hepatol.
- 2012 Mar;18(1):29-31.
- doi: 10.3350/kjhep.2012.18.1.29
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
-
Jung YK, Kim JH
- KMID: 1493571
- Clin Mol Hepatol.
- 2013 Mar;19(1):26-28.
- doi: 10.3350/cmh.2013.19.1.26
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Vogt-Koyanagi-Harada disease occurring during pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C
-
Lim JH, Lee YN, Kim YS, Kim SG, Jeong SW, Jang JY, Kim HS, Lee SH, Park TK
- KMID: 1105515
- Korean J Hepatol.
- 2011 Mar;17(1):61-65.
- doi: 10.3350/kjhep.2011.17.1.61
Vogt-Koyanagi-Harada (VKH) disease is a multisystem syndrome characterized by ocular (uveitis and retinal detachment), neurological (headache, tinnitus, and meningitis), and integumentary (vitiligo, alopecia, and poliosis) involvement. Although the pathogenesis of... -
- CITED
-
- Close
- SHARE
-
- Close
- Occurrence of diabetic ketoacidosis and autoimmune thyroiditis in a patient treated with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C
-
Lee YN, Jeong SW, Lim JH, Ryu YS, Jeon SR, Kim SK, Jang JY, Kim YS, Kim BS, Roh MO
- KMID: 1792598
- Korean J Hepatol.
- 2010 Jun;16(2):187-191.
- doi: 10.3350/kjhep.2010.16.2.187
Combined pegylated interferon and ribavirin therapy for chronic hepatitis C infection cause a wide range of side effects, including flu-like syndrome, hematological abnormalities, cardiovascular symptoms, gastrointestinal symptoms, pulmonary dysfunction, depression,... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Long-Term Follow Up of Combination Therapy with Interferon Alpha and Ribavirin for Chronic Hepatitis C in Korea
-
Kim JH, Han KH, Lee KS, Park YN, Ahn SH, Chon CY, Moon YM
- KMID: 1777167
- Yonsei Med J.
- 2006 Dec;47(6):793-798.
- doi: 10.3349/ymj.2006.47.6.793
Combination therapy with interferon alpha (IFN- alpha) and ribavirin for 24 or 48 weeks according to HCV genotype has improved the overall sustained virological response (SVR) rates to approximately 40%.... -
- CITED
-
- Close
- SHARE
-
- Close
- Hope for Cirrhosis Patients with Genotype 1 Hepatitis C Virus Who Failed the Previous Treatment
-
Kwon JH
- KMID: 2373327
- Korean J Gastroenterol.
- 2015 Aug;66(2):131-133.
- doi: 10.4166/kjg.2015.66.2.131
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of Efficacy of Peginterferon and Ribavirin Combination Therapy for Chronic Hepatitis C among Korean, Caucasian and Other Asians
-
Kim KA
- KMID: 1775791
- Korean J Gastroenterol.
- 2012 Nov;60(5):273-274.
- doi: 10.4166/kjg.2012.60.5.273
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatitis C virus infection in patients with hemophilia in Korea: Is antiviral therapy effective and safe?
-
Rou WS, Lee BS
- KMID: 2164361
- Clin Mol Hepatol.
- 2015 Jun;21(2):122-124.
- doi: 10.3350/cmh.2015.21.2.122
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Importance of Medication Adherence to Peginterferon-Ribavirin Combination Therapy in Patients with Chronic Hepatitis C
-
Goh PG, Kim MJ, Kim HJ, Eun HS, Kim ES, Kim YJ, Lee SY, Moon HS, Lee ES, Kim SH, Lee BS, Lee HY
- KMID: 1792786
- Korean J Gastroenterol.
- 2011 May;57(5):294-301.
- doi: 10.4166/kjg.2011.57.5.294
BACKGROUND/AIMS: The combination therapy with peginterferon and ribavirin is a standard treatment for patients with chronic hepatitis C. However, because of the long duration of the treatment and many complications,... -
- CITED
-
- Close
- SHARE
-
- Close
- Impact of adherence to peginterferon-ribavirin combination therapy in chronic hepatitis C patients on achieving a sustained virologic response
-
Jeong SW, Kim JD, Woo HY, You CR, Lee SW, Song MJ, Jang JW, Bae SH, Choi JY, Yoon SK
- KMID: 1374962
- Korean J Hepatol.
- 2009 Sep;15(3):338-349.
- doi: 10.3350/kjhep.2009.15.3.338
BACKGROUND/AIMS: Various predictive factors for peginterferon alpha and ribavirin therapy in chronic hepatitis C have been reported, but the effect of adherence to therapy has not been established. We investigated... -
- CITED
-
- Close
- SHARE
-
- Close
